For most of her life, Sarah felt a familiar, unsettling thump in her chest during her morning runs. Doctors called it benign. Then, a fainting spell led to an ultrasound, a thickened heart wall, and a diagnosis: hypertrophic cardiomyopathy. Just a few years ago, her path likely pointed toward open-heart surgery. Today, she manages her condition with a daily pill. Sarah’s story is becoming common, reflecting a seismic shift in cardiology.
New medications called cardiac myosin inhibitors, like mavacamten, are transforming care for obstructive HCM. They work by calming the overactive heart muscle. Dr. Srihari Naidu, a leading HCM expert, notes these drugs are so effective that invasive procedure volumes are dropping sharply. Alcohol septal ablation has fallen by about half. Surgical myectomy has declined even more.
This dramatic change brings a pressing concern. As drug therapy becomes the first line of defense, will the specialized skills for surgery and ablation fade? “I’m a little concerned that expertise may not be there,” Dr. Naidu explains. Myectomy requires a highly skilled surgeon performing numerous operations yearly to maintain proficiency. With fewer referrals, that vital experience pool could drain away.
The newest drug, aficamten, offers further refinement. Its shorter half-life allows for quicker dosage adjustments. It also appears to have fewer drug interactions. This is crucial for young women who may use oral contraceptives. These nuances mean treatment is no longer one-size-fits-all. Cardiologists now choose between options based on a patient’s age, lifestyle and other medications.
Yet, medications are not a simple cure-all. They require stringent monitoring through regular echocardiograms. For patients in remote areas, this creates a logistical burden. Some older patients with complex health issues might still benefit more from a one-time procedure. It permanently eliminates the obstruction and simplifies their long-term care.
The rise of drug therapy also highlights other needs. Treating HCM isn’t just about relieving symptoms. It involves genetic counseling for families, assessing sudden cardiac arrest risk and annual comprehensive check-ups. Dr. Naidu stresses that patients on these new drugs, especially those treated locally, must remain connected to specialized HCM centers. This ensures all aspects of their heart health are managed.
Paradoxically, these powerful new treatments are helping find more patients. When a condition has effective therapy, doctors look for it more aggressively. Increased awareness and advanced imaging are diagnosing people who lived for years with unexplained symptoms. This offers families a chance for early screening and intervention.
We stand at a crossroads in heart care. The promise of groundbreaking pills must be balanced with the preservation of procedural mastery. The goal is a complete toolkit—where medication, surgery and ablation are seen as complementary allies, not competitors. As we embrace this new era of treatment, we must ask: How do we safeguard all the skills necessary to heal every unique heart?
Key Points:
- Sarah’s journey with hypertrophic cardiomyopathy
- Introduction of cardiac myosin inhibitors
- Falling rates of invasive procedures
- Concerns about surgical expertise fading
- Effectiveness of the drug aficamten
- Need for ongoing monitoring of patients
| Procedure | Decline in Volume |
|---|---|
| Alcohol Septal Ablation | About 50% |
| Surgical Myectomy | Even more |
